Skip to content

Clinical study on Xiaopi Shengji Shengyang Decoction in the Treatment of Functional Dyspepsia with Emaciation

Clinical study on Xiaopi Shengji Shengyang Decoction in the Treatment of Functional Dyspepsia with Emaciation

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006019
Enrollment
Unknown
Registered
2022-05-19
Start date
2022-05-08
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Dyspepsia with Emaciation

Interventions

experimental group:Xiaopi Shengji Shengyang Decoction
Control group:Mosapride citrate tablets (lunambert pharmaceutical 5mg*36 tablets)

Sponsors

Tongde Hospital of Zhejiang Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Between 18 and 75 years of age; ? Meet the diagnostic criteria of Chinese and Western medicine for the disease; ? Those who have not taken drugs that can treat functional dyspepsia with emaciation, or have stopped taking drugs for more than 2 weeks despite taking drugs that can treat functional dyspepsia with emaciation; ? Have the ability of independent question and answer and understanding. Patients can complete the questionnaire by themselves or with help; ? The subjects voluntarily entered the group and signed the informed consent form; ? No other clinical trials affecting this study have been involved in recent three months.

Exclusion criteria

Exclusion criteria: ? Complicated with peptic ulcer, tumor, irritable bowel syndrome, esophagitis, intestinal metaplasia of gastric mucosa, etc; ? Suffering from metabolic diseases such as severe diabetes and hypothyroidism; ? Recent use of drugs or foods that affect the efficacy, and a history of alcoholism or drug abuse; ? Pregnant or preparing pregnant or lactating women; ? Patients with serious primary diseases and psychosis such as heart, brain, liver and kidney dysfunction and hematopoietic system; ? Unwilling to cooperate and allergic to drugs; ? TCM syndrome differentiation is not clear; ? Other situations that the researcher judges are not suitable for the inclusion criteria.

Design outcomes

Primary

MeasureTime frame
weight;

Countries

China

Contacts

Public ContactZhang Li
1534647339@qq.com15869281567

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026